TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit

Company Announcement - TG Therapeutics, Inc. will participate in the TD Cowen Immunology & Inflammation Summit virtually from November 12 – 13, 2025, with a fireside chat scheduled for November 12, 2025, at 10:00 AM ET [1] - A live webcast of the fireside chat will be available on the Company's website [2] Company Overview - TG Therapeutics is a fully integrated, commercial stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases [3] - The company has received FDA approval for BRIUMVI (ublituximab-xiiy) for treating adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease [3] - BRIUMVI has also received approval from several regulatory agencies outside the U.S. for treating adult patients with relapsing multiple sclerosis who have active disease defined by clinical or imaging features [3]